Suppression of dual-specificity phosphatase-2 by hypoxia increases chemoresistance and malignancy in human cancer cells

Journal of Clinical Investigation

Volumn 121, Issue 5, 2011, Pages 1905-1916

  Lin, Shih Chieh ^a   Chien, Chun Wei ^a   Lee, Jenq Chang ^a   Yeh, Yi Chun ^a   Hsu, Keng Fu ^a   Lai, Yen Yu ^a   Lin, Shao Chieh ^a   Tsai, Shaw Jenq ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DUAL SPECIFICITY PHOSPHATASE 2; HYPOXIA INDUCIBLE FACTOR 1ALPHA; PACLITAXEL;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CELL SURVIVAL; CONTROLLED STUDY; ENZYME PHOSPHORYLATION; GENETIC TRANSCRIPTION; HUMAN; HUMAN CELL; MALE; MALIGNANT NEOPLASTIC DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TRANSCRIPTION REGULATION; TUMOR REGRESSION; TUMOR XENOGRAFT;

ANIMALS; ANOXIA; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; DUAL SPECIFICITY PHOSPHATASE 2; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HELA CELLS; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; MAP KINASE SIGNALING SYSTEM; MICE; NEOPLASM TRANSPLANTATION; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 79955512439     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI44362     Document Type: Article

References (47)

1. Bruick RK, McKnight SL. A conserved family of prolyl-4-hydroxylases that modify HIF. Science. 2001;294(5545):1337-1340. (Pubitemid 33063099)
2. Maxwell PH, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271-275. (Pubitemid 29246458)
3. Jaakkola P, et al. Targeting of HIF-alpha to the von Hippel-Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation. Science. 2001;292(5516):468-472. (Pubitemid 32335942)
4. Semenza GL. Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics. Oncogene. 2010;29(5):625-634.
5. Brown JM, Wilson WR. Exploiting tumour hypoxia in cancer treatment. Nat Rev Cancer. 2004;4(6):437-447. (Pubitemid 38745529)
6. Owens DM, Keyse SM. Differential regulation of MAP kinase signalling by dual-specificity protein phosphatases. Oncogene. 2007;26(22):3203-3213. (Pubitemid 46763015)
7. Alonso A, et al. Protein tyrosine phosphatases in the human genome. Cell. 2004;117(6):699-711. (Pubitemid 38748887)
8. Theodosiou A, Ashworth A. MAP kinase phosphatases. Genome Biol. 2002;3(7):REVIEWS3009.
9. Rohan PJ, et al. PAC-1: a mitogen-induced nuclear protein tyrosine phosphatase. Science. 1993; 259(5102):1763-1766. (Pubitemid 23114665)
10. Zhang Q, Muller M, Chen CH, Zeng L, Farooq A, Zhou MM. New insights into the catalytic activation of the MAPK phosphatase PAC-1 induced by its substrate MAPK ERK2 binding. J Mol Biol. 2005;354(4):777-788. (Pubitemid 41735501)
11. Lang R, Hammer M, Mages J. DUSP meet immunology: dual specificity MAPK phosphatases in control of the inflammatory response. J Immunol. 2006;177(11):7497-7504. (Pubitemid 44846262)
12. Jeffrey KL, et al. Positive regulation of immune cell function and inflammatory responses by phosphatase PAC-1. Nat Immunol. 2006;7(3):274-283.
13. Wu J, Jin YJ, Calaf GM, Huang WL, Yin Y. PAC1 is a direct transcription target of E2F-1 in apoptotic signaling. Oncogene. 2007;26(45):6526-6535. (Pubitemid 47530605)
14. Yin Y, Liu YX, Jin YJ, Hall EJ, Barrett JC. PAC1 phosphatase is a transcription target of p53 in signalling apoptosis and growth suppression. Nature. 2003;422(6931):527-531. (Pubitemid 36433648)
15. Kim JW, Tchernyshyov I, Semenza GL, Dang CV. HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. Cell Metab. 2006;3(3):177-185.
16. Lu CW, Lin SC, Chen KF, Lai YY, Tsai SJ. Induction of pyruvate dehydrogenase kinase-3 by hypoxia-inducible factor-1 promotes metabolic switch and drug resistance. J Biol Chem. 2008;283(42):28106-28114.
17. Papandreou I, Cairns RA, Fontana L, Lim AL, Denko NC. HIF-1 mediates adaptation to hypoxia by actively downregulating mitochondrial oxygen consumption. Cell Metab. 2006;3(3):187-197.
18. Abdulkadir SA, et al. Impaired prostate tumorigenesis in Egr1-deficient mice. Nat Med. 2001;7(1):101-107. (Pubitemid 32095648)
19. Kaufmann K, Thiel G. Epidermal growth factor and platelet-derived growth factor induce expression of Egr-1, a zinc finger transcription factor, in human malignant glioma cells. J Neurol Sci. 2001; 189(1-2):83-91. (Pubitemid 32776653)
20. Mayer SI, Rossler OG, Endo T, Charnay P, Thiel G. Epidermal-growth- factor-induced proliferation of astrocytes requires Egr transcription factors. J Cell Sci. 2009;122(Pt 18):3340-3350.
21. Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res. 2002;62(12):3387-3394. (Pubitemid 34651384)
22. Lin MT, et al. Involvement of hypoxia-inducing factor-1alpha-dependent plasminogen activator inhibitor-1 up-regulation in Cyr61/CCN1-induced gastric cancer cell invasion. J Biol Chem. 2008;283(23):15807-15815.
23. Dong D, et al. Vascular targeting and antiangiogenesis agents induce drug resistance effector GRP78 within the tumor microenvironment. Cancer Res. 2005;65(13):5785-5791. (Pubitemid 40911182)
24. Zhu Y, et al. Hypoxia upregulates osteopontin expression in NIH-3T3 cells via a Ras-activated enhancer. Oncogene. 2005;24(43):6555-6563. (Pubitemid 41486638)
25. Gioeli D, Mandell JW, Petroni GR, Frierson HF Jr, Weber MJ. Activation of mitogen-activated protein kinase associated with prostate cancer progression. Cancer Res. 1999;59(2):279-284. (Pubitemid 29048852)
26. Hoshino R, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene. 1999; 18(3):813-822. (Pubitemid 29080340)
27. Sebolt-Leopold JS, et al. Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med. 1999;5(7):810-816. (Pubitemid 29318616)
28. Kohno M, Pouyssegur J. Targeting the ERK signaling pathway in cancer therapy. Ann Med. 2006; 38(3):200-211. (Pubitemid 43675585)
29. Hayman MJ, Enrietto PJ. Cell transformation by the epidermal growth factor receptor and v-erbB. Cancer Cells. 1991;3(8):302-307.
30. Bos JL. ras oncogenes in human cancer: a review. Cancer Res. 1989;49(17):4682-4689.
31. Wan PT, et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell. 2004;116(6):855-867. (Pubitemid 38410730)
32. Oka H, et al. Constitutive activation of mitogen-activated protein (MAP) kinases in human renal cell carcinoma. Cancer Res. 1995;55(18):4182-4187.
33. Givant-Horwitz V, Davidson B, Goderstad JM, Nesland JM, Trope CG, Reich R. The PAC-1 dual specificity phosphatase predicts poor outcome in serous ovarian carcinoma. Gynecol Oncol. 2004; 93(2):517-523. (Pubitemid 38507628)
34. Kim SC, Hahn JS, Min YH, Yoo NC, Ko YW, Lee WJ. Constitutive activation of extracellular signal-regulated kinase in human acute leukemias: combined role of activation of MEK, hyperexpression of extracellular signal-regulated kinase, and downregulation of a phosphatase, PAC1. Blood. 1999;93(11):3893-3899.
35. Caunt CJ, Armstrong SP, Rivers CA, Norman MR, McArdle CA. Spatiotemporal regulation of ERK2 by dual specificity phosphatases. J Biol Chem. 2008; 283(39):26612-26623.
36. Laderoute KR, Mendonca HL, Calaoagan JM, Knapp AM, Giaccia AJ, Stork PJ. Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun N-terminal protein kinase activity. J Biol Chem. 1999;274(18):12890-12897.
37. Richard DE, Berra E, Gothie E, Roux D, Pouyssegur J. p42/p44 mitogen-activated protein kinases phosphorylate hypoxia-inducible factor 1alpha (HIF-1alpha) and enhance the transcriptional activity of HIF-1. J Biol Chem. 1999;274(46):32631-32637. (Pubitemid 129535289)
38. Arbuck SG, et al. Clinical development of Taxol. J Natl Cancer Inst Monogr. 1993;(15):11-24.
39. McDaid HM, Horwitz SB. Selective potentiation of paclitaxel (taxol)-induced cell death by mitogen-activated protein kinase kinase inhibition in human cancer cell lines. Mol Pharmacol. 2001; 60(2):290-301. (Pubitemid 32678294)
40. MacKeigan JP, Collins TS, Ting JP. MEK inhibition enhances paclitaxel-induced tumor apoptosis. J Biol Chem. 2000;275(50):38953-38956. (Pubitemid 32058904)
41. Ma J, et al. Targeted knockdown of EGR-1 inhibits IL-8 production and IL-8-mediated invasion of prostate cancer cells through suppressing EGR-1/NF-kappaB synergy. J Biol Chem. 2009; 284(50):34600-34606.
42. Mahalingam D, Natoni A, Keane M, Samali A, Szegezdi E. Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells. Br J Cancer. 2010;102(4):754-764.
43. Gottesman MM, Ling V. The molecular basis of multidrug resistance in cancer: the early years of P-glycoprotein research. FEBS Lett. 2006; 580(4):998-1009. (Pubitemid 43185280)
44. Lin MT, et al. Cyr61 expression confers resistance to apoptosis in breast cancer MCF-7 cells by a mechanism of NF-kappaB-dependent XIAP up-regulation. J Biol Chem. 2004;279(23):24015-24023.
45. Gu T, et al. Osteopontin is involved in the development of acquired chemo-resistance of cisplatin in small cell lung cancer. Lung Cancer. 2009; 66(2):176-183.
46. Chien C-W, et al. Regulation of CD151 by hypoxia controls cell adhesion and metastasis in colorectal cancer. Clin Cancer Res. 2008;14(24):8043-8051.
47. Chuang PC, Wu MH, Shoji Y, Tsai SJ. Downregulation of CD36 results in reduced phagocytic ability of peritoneal macrophages of women with endometriosis. J Pathol. 2009;219(2):232-241.